Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

Servier Acquires Shire Oncology Business For $2.4bn

French pharma Servier takes step to meet its strategic ambition of becoming a global player in oncology by acquiring Shire's cancer franchise for $2.4bn

M & A Commercial Companies

Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year

Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.

Deals Financing Business Strategies
Advertisement

Companies

Set Alert for Companies

Latest From Companies

Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst

The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.

Business Strategies Companies

IOnctura CEO On Pipeline Strategy And Funding Goals

IOnctura’s CEO Catherine Pickering outlines the company’s business model and its approach to cancer R&D targeting the tumor microenvironment.

StartUps and SMEs Companies

How Will Novel Agents Impact The HIV Market?

ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research. 

Research & Development Business Strategies

Pipeline Growth Dropped Sharply in 2017 But Size Tops 15K

The number of products in active development by the pharma and biotech industries has topped 15,000 for the first time but the rate of the pipeline growth has slowed to just 2.7%, the lowest for five years, shows a new analysis by Citeline.

Analysis Companies

AXL Inhibition Specialist BerGenBio's $24m Private Placement To Fund Pipeline, Trials

BerGenBio CEO says the Norwegian biotech aims, either alone or in partnership, to develop and commercialize its lead asset through to marketing approval in a variety of cancers.

Financing ImmunoOncology

Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally

Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.

Analysis Business Strategies
See All

Deals

Set Alert for Deals

Latest From Deals

Servier's Shire Oncology Buy Gives Base For US Expansion

With the $2.4bn acquisition of Shire's oncology assets, including Oncaspar and Onivyde, the French drug maker has laid down a marker to become a key player in cancer and sees the US in particular as the land of opportunity.

M & A Cancer

Genentech Bets On Kineta's Early-Stage, Disease-Modifying Pain Therapy

Genentech partners with the Seattle biotech on a non-opioid approach to chronic pain. Kineta says there's disease-modifying potential.
Deals Neurology

Venture Funding Deals: MedImmune Spinout Viela Lands $250m Series A

China's JW Therapeutics nets $90m for cancer cell therapy, including backing from biotechs Celgene and WuXi. Meanwhile, Foghorn sounds out a $50m A round for its gene trafficking technology applications.

Deals Financing

Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally

Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.

Analysis Business Strategies

Genentech BD Director Reviews Recent Technology Deals

Mark Rowan, associate director of business development at Genentech, talks to Scrip at BIO-Europe Spring 2018 about the company's recent technology deals with DiCE Molecules and FinnGen.

Research and Development Strategies StartUps and SMEs

Tech Transfer Roundup: Vanderbilt Teams With Deerfield; Expands Cancer Pact With Boehringer

Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.

Research & Development Deals
See All

Strategy

Set Alert for Strategy

Latest From Strategy

AstraZeneca Bolstering India Play With $90m Investment Plan

AstraZeneca expects to invest $90m over five years to shore up its footprint in India – a market where the Anglo-Swedish major has introduced a string of new products but has also had a fair share of challenges.

Commercial Strategy

Pfizer Seeks To Block Infringement Of Sutent Patent In India

Pfizer is pushing ahead with legal action in India to ward off an alleged infringer of its patent on Sutent - a product that has had a checkered patent journey in the country.
Commercial Strategy

Secarna MD On Standing Out In A Crowd

Secarna's managing director Jonas Renz talks about the company's antisense platform and partnering strategy.

StartUps and SMEs Strategy

Orchard To Use Divested GSK Rare Disease Gene Therapies To Grow Globally

Orchard Therapeutics will acquire GSK’s portfolio of approved and investigational rare disease gene therapies, including EU-approved Strimvelis and additional late-stage gene therapies.

Analysis Business Strategies

Eisai Primes Push For Biogen MS Range In India

Eisai is straddling a mix of new opportunities for growth in India as it takes charge of sales of Biogen’s multiple sclerosis portfolio in the country and also eyes potential gains from its Japanese parent’s recent deal with Nichi-Iko.

Commercial Strategy

Alexion's Pipeline Rebuild Plan Targets Wilson's Liver Drug, More M&A Likely

Swedish target's sole product WTX101 is in Phase III trials for treating Wilson Disease. Alexion says expect more deals. 

Analysis Business Strategies
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Rigel Readies Tavalisse For Late-May Launch After FDA Approval

Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.

Approvals Immune Disorders

Call For India Compulsory Licenses For Last Resort TB Drugs

Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses. 

India Policy & Regulation

Amazon And The Case For Major Health Care Disruption

From drug delivery by drone to busting the drug rebate model, panelists at CNBC's inaugural health care conference had big visions for the changes Amazon could bring to health care.

Distribution Business Strategies
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.

Market Intelligence Infectious Diseases

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Merck came out ahead in the immuno-oncology combination showdown at AACR, with a strong overall survival benefit for Keytruda/chemo in the Phase III KEYNOTE-189 study in first-line NSCLC. The data were seen as practice-changing, but Bristol's CheckMate-227 trial of Opdivo/Yervoy failed to impress in the same way.

ImmunoOncology Market Intelligence

End In Sight: Humira Stacks Up 20 Years Of US Market Exclusivity

AbbVie, for the second time, has resolved a Humira patent dispute that protects the drug's US commercial exclusivity until 2023. The latest deal with Samsung Biopesis follows a similar agreement with Amgen, giving Amgen a five-month head start with its biosimilar. 

Legal Issues Biosimilars
See All
UsernamePublicRestriction

Register